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A B S T R A C T
Expression of fat mass and obesity-associated gene (FTO) and ADP-ribosylation factor-like 15 (ARL15) in human
islets is inversely correlated with HbA1c. However, their impact on insulin secretion is still ambiguous. Here in,
we investigated the role of FTO and ARL15 using GRINCH (Glucose-Responsive Insulin-secreting C-peptide-
modiﬁed Human proinsulin) clonal rat β-cells. GRINCH cells have inserted GFP into the human C-peptide insulin
gene. Hence, secreted CpepGFP served to monitor insulin secretion. mRNA silencing of FTO in GRINCH cells
showed a signiﬁcant reduction in glucose but not depolarization-stimulated insulin secretion, whereas ARL15
silencing had no eﬀect. A signiﬁcant down-regulation of insulin mRNA was observed in FTO knockdown cells.
Type-2 Diabetic islets revealed a reduced expression of FTO mRNA. In conclusion, our data suggest that ﬂuor-
escent CpepGFP released from GRINCH cells may serve as a convenient marker for insulin secretion. Silencing of
FTO expression, but not ARL15, inhibits insulin secretion by aﬀecting metabolic signaling.
1. Introduction
The FTO gene has been identiﬁed as an obesity-susceptibility gene
in multiple populations (Frayling et al., 2007; Dina et al., 2007; Scuteri
et al., 2007; Scott et al., 2007; Peeters et al., 2008). The gene was ﬁrst
discovered in mice where a deletion of 1.6 Mbp in chromosome 8 was
reported. Mice heterozygous for the deletion displayed a malformation
of forelimbs (fused toes) (Peters et al., 1999), while homozygous mice
died during mid-gestation of malformations of the head and face, with
defect in the central nervous system (CNS) development and growth
retardation. FTO acts as a 2-oxoglutarate (2OG)-dependent nucleic acid
demethylase (Gerken et al., 2007), therefore, it is suggested that FTO
might down-regulate genes involved in metabolism and lead to obesity.
FTO has been shown to play a vital role in obesity, appetite and
energy homeostasis (Church et al., 2009). The gene is ubiquitously
expressed in the brain, pancreatic endocrine cells (β and α) and adipose
tissue (Frayling et al., 2007; Gao et al., 2010; Stratigopoulos et al.,
2008; Taneera et al., 2012). Its expression is highest in the hypotha-
lamic region that regulates energy intake and expenditure (Poritsanos
et al., 2011). Fasted mice exhibit a signiﬁcant reduction of FTO
expression in the hypothalamic regions (Poritsanos et al., 2011). These
data suggest that variation in FTO resulting in decreased expression or
activity might provide a signal that promotes feeding and obesity.
Moreover, inactivation of the FTO gene in mice was shown to protect
from obesity, substantiating a central role of FTO in the control of en-
ergy expenditure (Fischer et al., 2009; Merkestein et al., 2014).
In humans, several studies have demonstrated single nucleotide
polymorphisms (SNPs) in the FTO gene that are associated with in-
creased body mass index (BMI) (Frayling et al., 2007; Scuteri et al.,
2007). Many studies have shown a vital role for FTO in the development
of obesity, regulation of appetite and energy homeostasis (Church et al.,
2009). Moreover, Genome-wide association studies (GWAS) have
identiﬁed genetic variants in the FTO gene that are associated with
increased risk of type 2 diabetes (T2D) (Frayling et al., 2007; Yajnik
et al., 2009). Furthermore, the FTO protein was reported to have a rapid
turnover in clonal pancreatic β cells and its overexpression enhanced
insulin secretion, suggesting that FTO could play an important role in β-
cell function (Russell and Morgan, 2011).
ARL15 belongs to the ADP-ribosylation factor (ARF) family. It has
been shown that ARL15 regulates membrane traﬃcking, lipid
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composition and the insulin signaling pathway (Donaldson and
Jackson, 2011). Several studies reported a strong association of ARL15
with increased risk of T2D, fasting insulin level and even β cell pro-
liferation (Scott et al., 2012; Thomsen et al., 2016). Also, it has been
reported that ARL15 acts as insulin-sensitizing protein to phosphorylate
the insulin receptor, (IR), the insulin receptor substrate-1 (IRS1) and
AKT kinase in the insulin pathway (Zhao et al., 2017). Recently, using
RNA-sequencing gene expression from human islets we reported that
both FTO and ARL15 are inversely correlated with HbA1c levels (Fadista
et al., 2014a). Still, the functional role of FTO and ARL15 in pancreatic
β cells remains unclear.
Pancreatic β-cells are specialized cells that regulate glucose home-
ostasis. Defects of insulin secretion in β-cells represent the culprit of
T2D, a disease that is expected to aﬀect more than 640 million people
by 2040 (http://www.diabetesatlas.org). Therefore, there is an urgent
need to understand mechanisms of dysregulated insulin secretion in
humans. One way to achieve this is to develop experimental models
that mimic real human pancreatic β-cells. Here we used the stable β-cell
line called GRINCH, derived from INS-1 cells but additionally expres-
sing a human proinsulin, in which the superfolder GFP is contained
within the C-peptide (Haataja et al., 2013).
In this study, we harness GRINCH cells to investigate the inﬂuence
of expression silencing of FTO and ARL15 on glucose-stimulated insulin
secretion. Our data indicate that FTO expression is reduced in islets
from T2D organ donors and that its silencing attenuates glucose-sti-
mulated insulin secretion. In contrast, knockdown of ARL15 did not
alter insulin secretion.
2. Materials and methods
2.1. GRINCH cells
The establishment of GRINCH cells has been described elsewhere
(Haataja et al., 2013). Brieﬂy, cDNA encoding superfolder GFP (sfGFP)
was ampliﬁed and ligated into the ApaI site located at the C-peptide
encoding sequence to make hPro-CpepSfGFP. Cells were cultured at
37 °C in a humidiﬁed atmosphere of 95% air and 5% CO2 in RPMI 1640
culture medium containing 11mM D-glucose (Gibco, Life Technologies)
supplemented with 10% fetal bovine serum, 100 units/ml penicillin,
100 μg/mL streptomycin, 10mM glutamine, 1mM sodium pyruvate,
10 mm HEPES, 50 μM β-mercaptoethanol (all from Sigma) and 0.1 mg/
mL G418 (CalBiochem, Germany). INS-1 (832/13) cells were cultured
under the same conditions but without G418.
2.2. Cell culture and insulin secretion assay
Conﬂuent plates containing (GRINCH or INS-1 (832/13) cells were
washed with 1mL pre-warmed Secretion Assay Buﬀer (SAB), pH 7.2
(114mM NaCl, 4.7mM KCl, 1.2mM KH2PO4, 1.16mM MgSO4, 20mM
HEPES, 2.5mM CaCl2, 25.5 mM NaHCO3 and 0.2% Bovine Serum
Albumin) containing 2.8mM glucose. The cells were then pre-in-
cubated for 2 h in fresh 2mL SAB with 2.8 mM glucose. Thereafter,
separate wells were incubated for 1 h in 1mL SAB containing either
2.8 mM glucose plus secretagogue (16.7mM glucose, 1 mM 3-iso-
butylmethylxanthine (IBMX) and 10 μM Forskolin). Secreted insulin
was measured from the supernatant using Coat-a-Count Insulin radio-
immunoassay kit (RIA) (Siemens), High Range Rat Insulin ELISA
(Mercodia, Uppsala, Sweden) and the GFP signals using TECAN plate-
reader (Inﬁnite M200, Switzerland). The ﬂuorescence intensity in the
plate-reader was adjusted for excitation wavelength 489 nm and emis-
sion wavelength 527 nm.
2.3. RNA interference
GRINCH (passage nr 14) or INS-832/13 (passage nr 59) cells were
cultured as previously described (Taneera et al., 2012) and transfected
using Lipofectamine RNAiMAX transfection reagent® (Invitrogen).
siRNA sequences against CHL1 (S 44135 and S 44134), FTO (S 146052
and S146053) and ARL15 (s187063) were purchased from Thermo-
Fisher. For control purposes, a previously described control sequence
Silencer® Negative Control #2 from Ambion was employed. Cells were
cultured in RPMI 1640 medium for 72 h at 37 °C in a humidiﬁed at-
mosphere containing 95% air and 5% CO2 in the presence of 40 nM
siRNA in 24-well cell culture microplates (250 000 cells/well). Three
days after transfection, insulin secretion measurements were performed
by RIA or ELISA and by TECAN plate-reader.
2.4. RT-qPCR
Total RNA was isolated with RNeasy Plus Mini Kit (Qiagen, Hilden,
Germany). RNA quality and concentration were measured using an
Agilent 2100 bioanalyzer (Bio-Rad, Hercules, CA, USA) and Nanodrop
ND-1000 equipment (NanoDrop Technologies, Wilmington, DE, USA).
cDNA was synthesized using RevertAid H Minus First Strand cDNA
synthesis Kit (Fermentas, Life Sciences). Analysis of gene expression
after knockdown was performed using the TaqMan qPCR with an ABI
Prism 7900 HT System (Applied Biosystems, USA) using gene-speciﬁc
primer probes for CHL1 (Rn01420997_m1), FTO (Rn01538186_m1),
ARL15 (Rn01494252_m1), Ins1 (Rn02121433_g1), Ins2
(Rn01774648_g1) and human Ins (Hs02741908_m1). (Applied
Biosystems, USA) in triplicates on 384-well plate. 1.2 ng cDNA was used
per well in 10-μL reaction volume containing TaqMan master mix
(Applied Biosystems, USA). The rat HPRT (Applied Biosystem) was used
to normalize gene expression by the ΔΔCt method, where the ﬁnal
normalized quantity was expressed as 2ˆ-(Ct target - Ct control).
2.5. RNA sequencing and human pancreatic islets
Human Islets from 204 cadaver donors (162 nondiabetic and 29
diabetic) of European ancestry were provided by the Nordic Islet
Transplantation Program and processed as previously described
(Taneera et al., 2015). Islets were obtained from 162 nondiabetic do-
nors (65 females, 97 males, age 57.9 ± 10, BMI 26.2 ± 3.8, HbA1c
5.7 ± 0.5) and 29 T2D donors (10 females, 19 males, age 61.1 ± 10,
BMI 27.6 ± 4.5, HbA1c 6.8 ± 0.8). Purity of islets was assessed by
dithizone staining and was 70% ± 17% in the nondiabetic and
67% ± 20% in the diabetic islets (p= 0.45). RNA sequencing was
done using Illumina's TruSeq RNA Sample Preparation Kit. Detailed
materials and methods for RNA-seq were previously described (Fadista
et al., 2014b). All procedures were approved by the ethics committees
at Uppsala and Lund University.
2.6. Apoptosis analysis
For apoptosis analysis, 1× 105 cells (72-h post-transfection) were
re-suspended in 500 μl of Annexin-V (1X) Binding Buﬀer (BD, USA). A
5 μl of Annexin V-FITC and 5 μl Propidium Iodide was added and in-
cubated at room temperature for 10min in the dark. Analysis with
Abbreviations
FTO Fat mass and obesity-associated
ARL15 ADP-ribosylation factor-like 15
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Flowcytometer (FACSAria III, BD) was performed using FITC channel
(515 nm) and PI at PE detector (585 nm), 30000 events are collected for
the analysis. Compensation was performed by using the single color
controls with Annexin FITC and PI.
2.7. Western blot analysis
Cells were lysed in ice-cold NP-40 (1.0% NP-40, 150mM of NaCl,
50 mM of Tris-Cl, pH 8.0) lysis buﬀer containing protease cocktail in-
hibitor tablets (Sigma) 72 h post-transfection. Protein concentrations
were quantiﬁed using the standard Bradford method (Bio-Rad, CA,
USA). A 30 μg sample of protein lysate was separated by 12% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto a nitrocellulose membrane (Bio-Rad) and then blocked
by 5% skimmed milk powder for 1 h at room temperature, washed with
(TBST), and the blot was probed with FTO (1:1000; #Ab92821 Abcam,
UK) antibody overnight at 4 °C. The secondary (anti-mouse and anti-
rabbit) antibodies were then reacted with the membrane at 1:1000
dilutions for 1 h at room temperature. Chemiluminescence was detected
using the ECL kit (Thermo Fisher). Protein band quantiﬁcation was
carried out using the Bio-Rad Image Lab software (ChemiDoc™ Touch
Gel and Western Blot Imaging System; Bio-Rad). β-actin was used as a
normalization control.
2.8. Statistical analysis
Data are presented as means ± S.D. Diﬀerences in expression levels
were analyzed by student's t-test or nonparametric Mann-Whitney tests.
P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. GFP signal intensity in GRINCH cells
To measure CpepGFP signal intensity of GRINCH cells, we prepared
lysate dilutions from GRINCH cells, with regular INS-1 (832/13) cells
used as a negative control. Lysates from GRINCH cells exhibited high
GFP intensity, which is gradually reduced with higher dilution (Fig. 1-
A). We were able to detect CpepGFP signals from the lysate preparation
even at dilution factor 1:40 compared to INS-1 (832/13) cell lysate,
which showed no GFP signal intensity.
3.2. GRINCH cells expressed a human and rat insulin gene cDNA along with
endogenous rat insulin
As previously described, INS-1 (832/13) cells were derived from
INS-1 cells and engineered to stably express human insulin cDNA
(Asfari et al., 1992). Moreover, the human insulin content of GRINCH
and INS-1 (832/13) cells was similar and both exhibited stimulus-de-
pendent secretion (Haataja et al., 2013). To conﬁrm expression of
human and rat insulin mRNA in GRINCH cells, RT-qPCR was performed
using distinct sets of amplifying primers. As expected, both human and
rat insulin mRNA was expressed in GRINCH cells. The Ct values for the
rat Ins1 was 13, rat Ins2 19 and for the human Ins gene was 25 (Fig. 1-
B).
3.3. Insulin secretion in GRINCH cells
To test secretegogue-stimulated insulin secretion in GRINCH cells,
cells were seeded (700 000 cell/well) and grown overnight. The next
day, cells were stimulated with 2.8, 6, 10, 16.7 mM glucose, 1 mM
IBMX or 10 μM Forskolin for 1 h. The supernatant containing secreted
insulin was analyzed using RIA and by measuring the GFP signals in a
TECAN plate-reader. RIA measurements showed a 3-fold increase be-
tween the basal level (2.8 mM Glucose) and secretion level (16.7 mM
Glucose) and almost 6-fold between the 16.7 mM glucose and 16.7 mM
glucose with IBMX or Forskolin (Fig. 1 –C). Using the GFP signal as a
surrogate marker to measure insulin secretion, we observed a 2-fold
increase between the basal and stimulating section level (16.7 mM) and
an almost 5-fold increase between 16.7 mM glucose and IBMX or For-
skolin (Fig. 1-D). Insulin secretion measured by RIA and plate-reader
were highly correlated (R2=0.99) (data not shown). The percentage of
insulin release measured as a fraction of insulin content was 1.8% using
CpepGFP signal assay, while it was 2% using the ELISA assay after
16.7 mM glucose stimulation.
3.4. GRINCH cells as a tool to study pancreatic β cell function
The CHL1 gene encodes for a neural adhesion molecule, it has been
suggested that CHL1 might be involved in the development of islet
structure and determine the distribution of β, α, and δ cells in pan-
creatic islets. Previously, we reported that expression of CHL1 in human
islets is strongly related to HbA1c and insulin secretion and decreased in
Fig. 1. GFP signal intensity, Ins genes expression
and insulin secretion in GRINCH cells. (A)
Sonicated lysates from GRINCH and regular INS-832/
13 cells were diluted in H2O and CpepGFP signals
were measured using the TECAN plate-reader. (B) Ct
values of qRT-PCR demonstrate that GRINCH cells
express both rat (Ins1 and Ins2) and human insulin
genes. HPRT1 was used as a house keeping gene. (C,
D) GRINCH cells were stimulated with 2.8, 6, 10,
16.7 mM glucose, 16.7 mM glucose + 1 mM IBMX or
10 μM Forskolin for 1 h. Supernatants containing
secreted insulin were measured by RIA (C) and
CpepGFP signals using TECAN plate-reader method
(D).
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islets and β cells from patients with T2D (Taneera et al., 2012). Im-
portantly, we showed that siRNA gene silencing of CHL1 in INS-1 (832/
13) cells signiﬁcantly reduced insulin secretion.
Thus, to validate GRINCH cells as a tool for functional studies of
pancreatic β cells, we silenced the expression of CHL1 in GRINCH cells.
Knockdown eﬃcacy measured by RT-qPCR after 48 h revealed almost
50% decreased expression of CHL1 (Fig. 2-A. The supernatants con-
taining secreted insulin from transfected cells were analyzed after
glucose stimulation using ELISA assay and TECAN plate-reader for
CpepGFP signal intensity. We noticed a signiﬁcant reduction in insulin
secretion (45%, p < 0.05) in silenced cells compared to negative
control siRNA using ELISA assay (Fig. 2-B), whereas a 37% reduction in
insulin secretion was observed using the CpepGFP signal measurement
(p < 0.05) (Fig. 3-C). These results further validate the use of GRINCH
cells for screening of altered insulin secretion by monitoring ﬂuores-
cence.
3.5. Silencing of T2D candidate genes
Fadista et al. have identiﬁed a list of 17 established T2D and gly-
cemic associated loci (PCSK1, SLC30A8, G6PC2, IKBKAP, FTO, VPS13C,
PDX1, ARL15, ADAMTS9, JAZF1, RASGRP1, PROX1, SLC2A2, GRB14,
AMT, PTPRD and IRS1) whose gene expression proxies in human islets
using RNA-sequencing are associated with HbA1c levels (Fadista et al.,
2014b). Of the 17 genes, 2 genes (ARL15 (ADP-ribosylation factor-like
15) and FTO were selected for further investigation in GRINCH cells.
Speciﬁcally, siRNA against FTO and ARL15 were used to silence the
expression of each gene in GRINCH cells. Transfection eﬃcacy mea-
sured by RT-qPCR after 48 h resulted in almost a 90% decreased ex-
pression of FTO and 70% for ARL15 (Fig. 3-A). Similar reduction of FTO
protein expression was observed by western blot analysis. (Fig. 3-B).
The supernatants containing secreted insulin from transfected cells
were analyzed after glucose stimulation using ELISA and TECAN plate-
reader for GFP signal intensity. Insulin secretion measurement after
72 h in FTO knockdown cells (measured by ELISA) in response to
16.7 mM glucose showed almost 50% reduction (p < 0.5) and 40%
reduction (p < 0.05) as measured by CpepGFP compared to negative
control cells (Fig. 3-B and C). As the ﬁrst siRNA silencing of FTO (siFTO-
1) revealed a decrease in insulin secretion, we further conﬁrmed the
ﬁnding using another siRNA (siFTO-2) (Fig. 3-B and C). Moreover, FTO
knockdown reduced the ﬁrst phase of insulin secretion as measured at
10min after glucose stimulation compared to negative control cells
(Supplementary Fig. 1).
Silencing of ARL15 showed no impact on insulin secretion compared
to siRNA negative control measured by ELISA or GFP intensity (Fig. 3-B
and C).
To elucidate how siRNA gene silencing of FTO contributes to pan-
creatic β-cell failure, we performed several functional studies to iden-
tify the possible mechanism.
First, to explore whether the exocytosis machinery is defective upon
silencing of FTO, we stimulated insulin exocytosis with depolarizing
(35mM) KCl, and this showed no diﬀerence between transfected cells
and controls (Fig. 3-D and E).
Next, we stained transfected cells with Annexin-V/PI to investigate
the cell death of INS-1 (832/13) cells following siRNA silencing. Since
Annexin-V is monitored using the FITC channel we could not use the
GRINCH cells because of ﬂuorescence overlap. As shown in Fig. 4-A, the
ratio of the apoptotic cells between FTO knockdown cells and siRNA
negative control were similar. The percentage of early apoptotic cells
(0.2% vs. 0.3%) or late apoptotic cells (0.1% vs. 0.2%) between FTO
knockdown cells and control siRNA (Fig. 4-A).
Finally, we analyzed the mRNA expression level of Ins1 and Ins2
genes in transfected GRINCH cells. qRT-PCR analysis showed a sig-
niﬁcant decrease of both Ins1 (p= 0.01 and Ins2 (p= 0.02) mRNA
expression in transfected cells compared to negative siRNA control
(Fig. 4-B). This was further conﬁrmed by measuring the GFP signal from
cell lysates which showed almost 30% decrease in FTO transfected cells
(Fig. 4-C).
3.6. Expression of FTO in human islets
Using RNA-sequencing data from human pancreatic islets, we in-
vestigated the expression of FTO in diabetic (n=30) and nondiabetic
donors (n=172). FTO expression was found to be lower in T2D islets
(p= 0.058, adjusted for age, sex and BMI) than in non-diabetic islets
(Fig. 5-A). Moreover, stratifying the donors into normal glucose tolerant
(NGT; HbA1c < 6.0) and T2D (HbA1c < 6.5) showed that mean ex-
pression of FTO was signiﬁcantly lower in T2D donors (p= 0.04; ad-
justed to age, sex and BMI) (Fig. 5-B).
4. Discussion
Several studies have suggested a potential role for FTO in insulin
secretion (Russell and Morgan, 2011; Kirkpatrick et al., 2010). Kirk-
patrick et al., reported that FTO mRNA level was reduced in puriﬁed
human β-cells from a small number of T2D patients compared with non-
diabetic controls (Kirkpatrick et al., 2010). Fadista et al. found FTO to
be suppressed in islets of T2D patients (21), which we conﬁrm in a
larger number of organ donor islets. It is likely that the reported in-
crease in DNA methylation of the FTO gene contributes to the lower
mRNA expression (Dayeh et al., 2014).
However, the role of FTO in insulin secretion is controversial. Here,
we demonstrate that siRNA silencing of FTO results in reduced glucose-
stimulated insulin secretion without aﬀecting the stimulant action of
depolarizing potassium concentrations. This indicates that the exocy-
totic machinery is not altered by FTO silencing. In agreement with our
ﬁnding, Russell et al. showed that conditional expression of the FTO
gene product in INS-1 cells enhanced ﬁrst phase insulin secretion sti-
mulated with 20mM glucose (Russell and Morgan, 2011). However, the
increase in insulin secretion in this case was attributed to the exocytosis
machinery rather than upregulated insulin biosynthesis.
Inconsistent with our ﬁndings and those of Russel and Morgan
(Russell and Morgan, 2011) was the observation that FTO over-
expression in MIN6 clonal mouse β-cells by lentivirus resulted in a
Fig. 2. CHL1 knockdown in GRINCH cells. (A)
Knockdown eﬃciency of siRNA of CHL1 in GRINCH
cells as determined by RT-qPCR. (B) Insulin secretion
as assessed by RIA in response to 2.8 mM and
16.7 mM glucose at 72 h post siRNA transfection
during 1-h static incubation. Insulin secretion ex-
pressed as a fold increase (insulin secreted at
16.7 mM at 2.8 mM glucose). (C) Insulin secretion
measured as GFP intensity by plate-reader. Bars re-
present mean ± SD. *p < 0.05.
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signiﬁcant reduction in insulin secretion in the presence of 20mM
glucose or KCl (Fan et al., 2015). Interestingly, silencing of FTO in MIN6
cells revealed no eﬀect on insulin secretion. A possible explanation for
the discrepancy could relate to the diﬀerent approach for FTO silencing
by siRNA, vs. overexpression by lentivirus. INS-1 cells and GRINCH
cells were derived from a rat insulinoma, while MIN6 cells are of
murine origin. Therefore, species-related variations could underlie the
discrepant results. Species-speciﬁc results regarding the role of FTO
have indeed been reported. For example, while fasted mice exhibit a
signiﬁcant decrease in hypothalamic FTO expression (independently of
leptin levels) as compared to fed controls (Gerken et al., 2007), fasted
rats show increased FTO expression in the hypothalamus (Fredriksson
et al., 2008). Moreover, loss of FTO function in mice reduces fat mass
through increased energy expenditure but not decreased energy intake
(Church et al., 2009). It has been suggested that FTO impacts feeding
behavior by aﬀecting neuropeptide Y expression in the hypothalamus in
rodents (Alkan et al., 2017). In man, FTO-SNPs are associated with
appetite and food intake but not energy expenditure (Fischer et al.,
2009; Do et al., 2008). Thus, it is likely that the discrepancy between
species reﬂects diﬀerences of FTO actions.
GWAS have implicated ARL15 in several metabolic traits (Scott
et al., 2012; Thomsen et al., 2016). Despite the fact that ARL15 ex-
pression was correlated with HbA1c levels, our results showed that gene
silencing of ARL15 in INS-1 cells had no eﬀect on insulin secretion.
During the preparation of this study, Rocha et al. reported studies on
ARL15 in insulin signal transduction and adipocytes diﬀerentiation in
3T3-L1 preadipocytes (Rocha et al., 2017). In ARL15 knockdown cells,
there was no eﬀect on insulin-stimulated phosphorylation of AKT or
ERK nor on insulin-stimulated glucose uptake. However, signiﬁcant
impairment of adiponectin secretion was observed.
Here we report the use of CpepGFP signal intensity from GRINCH
cells as a new tool to assay pancreatic β-cell function. GRINCH cells
were developed to study proinsulin traﬃcking, processing and secretion
from pancreatic β-cells. The superfolder GFP inserted in human
proinsulin C-peptide showed excellent glucose-stimulated insulin se-
cretion upon exposure to high glucose doses and unique feature based
on the ability to exhibit a recoverable CpepGFP signal (Haataja et al.,
2013). This feature of GRINCH cells allowed us to exploit the CpepGFP
signal in GRINCH cells as a marker of β-cell function. We noticed that
secretion data from stimulated GRINCH cells measured by GFP-plate
Fig. 3. FTO and ARL15 knockdown in GRINCH cells. (A) knockdown eﬃciency of siRNA for ARL15 (s187063), FTO-1 (s146052) and FTO-2 (s146053) in INS-1
(832/13) cells. (B) Western blot bands of FTO protein expression relative to the endogenous control protein β-actin in FTO knockdown cells and cells transfected with
negative siRNA control. (C) Insulin secretion in response to 2.8 mM and 16.7mM glucose 72 h post siRNA transfection measured during 1-h static incubation. Cells
transfected with siRNA against FTO showed almost a 50% reduction in insulin secretion in both siRNAs, whereas those with ARL15 showed no eﬀect compared to
siRNA negative control (NC). (D) Insulin secretion measured by Cpep-GFP intensity by plate-reader showed a 40% reduction with FTO transfected cells but not
ARL15. (E & F) Transfected cells with siRNA against FTO-2 were stimulated by a depolarizing agent (35 mM KCL) and measured by ELISA and GFP intensity. No
signiﬁcant diﬀerences between transfected and control cells were observed. Insulin secretion was normalized for cell count. Data are shown from three independent
experiments for each siRNA. Bars represent mean ± SD. *<0.05, **< 0.01.
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reader assay were overall similar to results obtained with RIA or ELISA,
except for a marginally smaller fold-stimulation. However, such a dif-
ference between the assays was not statistically signiﬁcant (p > 0.05).
Herein, we have used relatively early passage number of GRINCH cells,
stability of the CpepGFP over multiple passages need to be tested.
Several reports have described surrogate markers for insulin
secretion in pancreatic β-cell lines by fused GFP or luciferase (Burns
et al., 2015; Pouli et al., 1998). Recently, Bruns et al. reported a lu-
minescent insulin secretion assay that enables large-scale investigation
of β-cell function (Burns et al., 2015). Speciﬁcally, Bruns et al. inserted
a Gaussia luciferase into the C-peptide portion of proinsulin, and they
found that upon stimulation with secretagogues, β-cells expressing this
Fig. 4. Assessment of apoptosis in INS-1 cells. (A) Cell transfected with siRNA negative control or siRNA against FTO were stained with Annexin V-FITC and PI and
analyzed by ﬂow cytometry. (B) qPCR expression analysis of Ins1 and Ins2 genes in GRINCH cells transfected with negative control or siRNA against FTO. Cell lysate
from transfected cells (with negative control or FTO) were used to measure GFP intensity as indicator for insulin content. Bars represent mean ± SD. *<0.05.
Fig. 5. FTO gene expression in human pancreatic islets. FTO mRNA expression revealed lower level in pancreatic islets from T2D donors compared to those from
non-diabetic controls (B), the reduced expression was signiﬁcant when donors were stratiﬁed for NGT vs T2D.
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reporter secreted luciferase in close correlation with insulin. In the case
of GRINCH cells, insulin secretion measurement is performed directly
by plate-reader assay of the supernatants after secretagogues simula-
tions while the luciferase activity requires adding coelenterazine sub-
strate to the supernatant before read-out.
Out of the 17 established T2D genes whose gene expression proxies
are associated with HbA1c, eight genes (SLC30A8 (Wijesekara et al.,
2010), G6PC2 (Pound et al., 2013), PCSK1 (Ravassard et al., 2011),
PDX1 (Stoﬀers et al., 1997), VPS13C (Grarup et al., 2011), RASGRP1
(Taneera et al., 2012), SLC2A2 (Guillam et al., 1997), and IRS1 (Meur
et al., 2010)) were excluded as they have already been implicated for a
role in insulin secretion. Additionally, previously we showed that gene
silencing of ADAMTS9 and JAZF1 has no impact on insulin secretion
(Taneera et al., 2015). For the other 7 genes, the selection criteria in-
cluded expression in β-cells based upon previously published RNA-se-
quencing expression data from sorted human pancreatic endocrine cells
(Blodgett et al., 2015). The FTO, IKBKAP and ARL15 genes were found
to have the highest expression in sorted β-cells. ARL15 is a GTP-binding
protein that has been shown to inﬂuence adiponectin levels (Richards
et al., 2009). IKBKAP encodes a scaﬀold protein and a regulator for 3
diﬀerent kinases involved in pro-inﬂammatory signaling. Mutations in
this gene have been associated with familial dysautonomia
(Slaugenhaupt et al., 2001). Based on gene function, only FTO and
ARL15 were selected for functional studies in GRINCH cells.
Conclusions We demonstrate the validity of GRINCH cells as a new
tool to study pancreatic β-cell secretion. The cells retain insulin secre-
tion responses to glucose and exhibit similar physiologic characteristics
comparable to those of INS-1 (832/13) cells. This tool may serve as a
rapid, and inexpensive method for screening of compounds, in order to
investigate molecular mechanisms inﬂuencing insulin secretion.
Knockdown of FTO expression in GRINCH cells inhibits insulin secre-
tion, whereas no eﬀect for ARL15 was observed. The reduced insulin
secretion in FTO knockdown cells was associated with decreased insulin
mRNA levels while cell viability was preserved. Additional work should
pin-point the exact role of the FTO gene as a regulator of pancreatic β-
cell function.
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